ロード中...
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark
Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma....
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485790/ https://ncbi.nlm.nih.gov/pubmed/26140249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1058037 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|